Heart Failure Associated with Type 2 Diabetes

Susan Thomas, MD and Curtis Triplitt, PharmD, CDCES

This webinar will provide a basic overview of diabetic / non-diabetic cardiomyopathy and clinical perspectives on HFpEF and HFrEF. Participants will be able to understand treatment options for HF in patients with and without diabetes.

Wednesday, May 27, 2020 at 1:00 pm EST

Cardiovascular Disease and Type 2 Diabetes:
Defining the Therapeutic Crossroads

John Venditto, MD

Explore the relationships between type 2 diabetes and cardiovascular disease (CVD) with CVD risk factors. The presenter will discuss definitions of primary and secondary prevention of CVD, including long-term oral anti-platelet trials in secondary prevention in T2D. You'll come away with an understanding of lipid and triglyceride management.

Wednesday, July 22, 2020 at 1:00 pm EST

2020 Guideline Updates and Implications
to Patient Care

Ted Okerson, MD, FACP, FACE, FTOS and Paul Tomasic, MD

Understand changes to the ADA/EASD treatment guidelines and importance of treating CVD and DKD as well as the impact of treatments on glycemia and weight. The presenters will facilitate a discussion on this impact to providers and patients.

Wednesday, June 24, 2020 at 1:00 pm EST

Relationship of Type 2 Diabetes and Diabetic Kidney Disease: Progression of these chronic conditions

Speaker TBA

This webinar will give you an understanding of how type 2 diabetes and diabetic kidney disease (DKD) are related. Understand the continuum of disease progression and key points of intervention, as well as the treatment options when treating complications of DKD.

Wednesday, September 23, 2020 at 1:00 pm EST

Type 2 Diabetes and Kidney Disease: Patient engagement and how to manage chronic conditions

Robert M. Perkins, MD, MPH and Ted Okerson, MD, FACP, FACE, FTOS

Understand key points of clinical intervention, as well as how to engage patients in discussions about chronic conditions early in development of disease, and how to encourage adopting healthy behaviors.

Wednesday, October 21, 2020 at 1:00 pm EST

SGLT-2 Inhibitor Overview and Emphasis
on Cardio-Renal Axis

Speaker TBA

This webinar will go over how SGLT-2 inhibition impacts the physiology of the kidney and heart. Understand the clinical effects on glycemia, MACE, hHF, and renal endpoints in diabetes, as well as the evolving landscape and use of these agents in patients without diabetes.

Wednesday, December 2, 2020 at 1:00 pm EST

GLP-1 Physiology and Evolving Clinical Data

Originally presented on February 26, 2020 by James Ruggles, PhD, and Curtis Triplitt, PharmD, CDE

This webinar provides an overview of the actions of GLP-1 receptor agonists in the body, the clinical effects of GLP-1 receptor agonists on glycemia, MACE, and renal endpoints; as well as the impact of higher concentrations on weight.

Upon completion of this activity, participants will be able to:

1. Describe the actions of GLP-1 receptor agonists in the body
2. Explain the clinical effects of GLP-1 receptor agonists on glycemia, MACE, and renal endpoints
3. Review impact of higher concentrations on weight

Measures Beyond A1C and Their Impact on Treatment

Originally presented on March 18, 2020 by Jonathan L. Respress, PhD and Davida F. Kruger, MSN, APN-BC, BC-ADM

This webinar reviews how postprandial glucose (PPG) and fasting plasma glucose (FPG) impact A1C and what the impact of glucose-dependency and treatment options is. The presenters provide an understanding of the role of CGM and its impact on treatment decisions, as well as what “time in range” is and why it matters.

Upon completion of this activity, participants will be able to:

1. Review glucose profiles to understand the physiology of glucose fluctuations in normal glucose homeostasis and in T2D
2. Understand the hyperglycemic peaks and hypoglycemic troughs that can occur in T2D and potential clinical relevance of time spent outside euglycemic range
3. Discuss the role of glucose fluctuations as a potential metric for guiding treatment in T2D
4. Review the effects of new GLDs on glucose fluctuations in the setting of T2D